2022 Global Life Sciences Outlook
Digitalization at scale: Delivering on the promise of science
Life sciences companies face distinct challenges with their very visible role in drug pricing and access to medicines, and the pandemic only underscored this focus. Even during these unprecedented times over the last two years, many life sciences organizations have witnessed a scientific breakthrough. Shifts to more data-driven approaches across the value chain, greater collaborations, digital transformation, and the advancing CEO priorities are driving the change. A new bar has been set and companies are now willing to move beyond convention to solve the toughest challenges and stand to reap the biggest benefits.
Our 2022 Global Life Sciences Outlook focuses on the current state of the sector, explores seven trends shaping the industry and prepares stakeholders to take advantage of the many opportunities the pandemic has surfaced and accelerated. In the year ahead, forward-looking companies will adopt a think-digital-to-be-digital mindset and consider how these technologies can augment human capabilities and update execution of processes.
Explore and download the key issues below:
Explore our previous outlooks
Review or download previous life sciences sector outlooks.
Interested in the trends and issues impacting health care providers, health plans, and government health organizations? Explore our global health care sector outlook.
Are we finally seeing the long-promised transformation?
Market access strategy is critical to therapy launch success, but traditional approaches can lack nuance. Our research suggests that an archetype-based approach to enable targeted market access strategies may be more useful.